Background: RNA binding motif (RBM) proteins, RBM10v1, RBM10v2 and RBM5 share a high degree of the conserved domains. So far, the drug-sensitivities of the RBMs in tumor cells have not been fully examined. Objective: The expression profiles of RBM10 and RBM5 in several virus-transformed tumor cells, and the effect of the most established antitumor agents, actinomycin D and doxorubicin, were investigated. Methods and Results: Doxorubicin and actinomycin D differentially reduced RBM10 and RBM5 protein, respectively in both of HeLa and COS-7 cells. RBM10 protein was highly sensitive to doxorubicin in HeLa, COS-7 and A549 cells. In silico analysis revealed the several sumoylation sites of RBM10 and its sumoylated form could be targeted for the activated ubiquitin proteasome system. Actinomycin D affected the nuclear speckles localization of RBM10 and RBM5 in COS-7 and A549 lung carcinoma cells. Addition of actinomycin D in the culture medium and following culture for 3-4 hours promoted the prominent nuclear speckles of RBM10v2-GFP and RBM5.
Introduction
Nuclear speckles enrich in the pre-mRNA splicing regulators and organize active genes (1). The initial step of splicing is binding of U1 snRNP with the pre-mRNA to form spliceosomal E complex (2). RBM5 and RBM10 assemble with the stalled spliceosome A complex and precatalytic B complexes, respectively (3). The precatalytic spliceosome B complex assembles with preformed U4/U6/U5 tri-snRNP. Importantly, ubiquitylation and sumoylation involve in the modification and assembly of spliceosomal components (4,5).
RBM10 is proposed as an important regulator of alternative splicing (6). The human RBM10 gene is located at a region of chromosome X, p11.3-p11.23 and frequently mutated in lung adenocarcinomas (7) . Frame-shift mutations of the RBM10 gene cause X-linked disorders in affected males (8, 9) . The human RBM5 gene is located at a region of chromosome 3, 3p21.3 which is frequently deleted in a variety of cancers (10). RBM5 or RBM10 involves in alternative splicing of Fas pre-mRNA (11, 12) . RBM10 pre-mRNA is alternatively spliced to RBM10v1 (930 AA) and RBM10v2 (852AA). The two RBM10 variants and RBM5 (815AA) share significant sequence similarities (13). Doxorubicin (DOX), a toposiomerase II inhibitor inhibits the synthesis of DNA and RNA, activates caspase-2 and caspase-3 (14-17), and triggers the activation of ubiquitin proteasome system (18) . Actinomycin D (AcD) inhibits the processes of RNA elongation and DNA replication, and activates several caspases (19) (20) (21) . DOX generates free radicals and damages cardiac cellular membranes (22) . In addition, DOX and a low concentration of AcD are known as nucleolar stress inducers (23). AcD promotes the nuclear speckles-targeting of RBM10, RBM6, SF3b 155 and SR related protein (24) (25) (26) (27) . So far, the effects of doxorubicin and AcD on the expression of the RBMs have not been fully investigated.
HeLa and COS-7cells are hyperproliferative and known as SV40-and HPV-18-transformed cells, respectively. In the present study, protein levels of RBM10 and RBM5 were examined in HeLa, COS-7, A549 lung carcinoma cells, differentiated by Olympus μ -7000 digital camera and quantified by the image analysis software, Image-Pro plus (Media Cybernetics, MD.
USA).
Construction of expression vectors:
An expression vector of human PML-Ⅳ(isoform 6, protein NP_002666) was provided by Dr Kung Sang Chang (University of Texas, USA). A GFP-fused construct of PML-Ⅵ (isoform1, GenBank at NCBI, accession no.AAA60125) was provided by Dr. Katano (National Institute of infectious diseases, Tokyo, Japan -759] and the N-terminal region of RBM10v2 [#1-629] were amplified as described above and cloned into the pDsRed1-N1 and pNLS-EGFP-N3 vector, respectively. The coding sequences of RBM10 were confirmed by restriction digestion. The full length RBM10-GFP and RBM5-GFP proteins were detected with the specific antibodies.
Antitumor agents, transfection and fluorescence microscopy: COS-7 or HeLa cells grown in 6-well plates were cultured in the presence or absence of doxorubicin (DOX) (44583: Sigma-Aldrich) or Actinomycin D (AcD) (A1410: Sigma-Aldrich) for 6 or 16 hours and the cell lysates were prepared.
A549 or COS-7 cells were cultured in Falcon 4-well culture slides (Lifetecnologies Inc. USA) until 80%-confulency was reached. Subconfluently grown A549 cells were exposed to DOX (0.5 µM or 1 µM) for 3 or 20 hours. The cells were fixed in 4% formalin-PBS for 10 minutes, washed in PBS and permealized in 1% Triton X-100-PBS for 5 minutes and stained with the primary anti-RBM5 or anti-RBM10 antibody and the Alexa 488 -or Alexa 555 -labeled anti-rabbit IgG.
COS-7 cells grown in an each well were transfected with 1μg of the expression vector of RBM10v2-RFP and 5μl of Lipofectoamin 2000 reagent, cultured for 48 hours at 37 ºC and exposed to 0.5 µM or 1 µM DOX for 8 hours. COS-7 cells were transfected with 1μg of the expression vector of RBM10v2-GFP as described above and exposed to 1 µM AcD for 4 or 20
hours. The nuclear speckles targeting of the RBMs were examined by Keyence BZ8000 fluorescence-phase contrast microscopy (Keyence Japan, Osaka).
COS-7 and A549 cells were transfected with 1μg of the expression vector of the N-terminally truncated RBM10v2-RFP, C-terminally truncated RBM10v2-GFP or RBM5-GFP, and exposed to 1 µM AcD for 3 hours, washed in PBS and fixed.
Subnuclear compartments-targeting of the GFP (or RFP)-fused RBMs was examined by fluorescence-phase contrast microscopy as described above. For human RBM10v1 and RBM10v2, the forward primer RBM10A, 5'-AGGGCAAGCATGACTATGA-3' and reverse primer RBM10B, 5'-GTGGAGAGCTGGATGAAGG-3' were used as described by (30) For human RBM5 (LUCA-15), the forward primer RBM5, LU15 (2) 5'-GACTACCGAGACTATGACAGT-3' and reverse RBM5, LU15(3) 5'-AGAGGACAGCTGCACAAATGC-3' were used as described by . For human exon 6-skipped Fas 5-7, the forward primer CCAAGTGCAAAGAGGAAGTGA and reverse primer GGAGATTCATGAGAACCTTGG were used, and for human exon 6-included Fas 5-6-7, the forward primer TGCAAAGAGGAAGGATCCAG and the reverse primer TTCTGTGTTTCTGCATGTTTT were used as described by (11).
Reverse transcription and PCR analysis:
For human GAPDH, the forward primer 5'-AAGGCTGAGAACGGGAAGCTTGTCATCAAT-3' and reverse primer 5'-TTCCCGTCTAGCTCAGGGATGACCTTGCCC-3' were used as described by Nishio et.al., (32) . The amplified cDNA products were separated on agarose gels (1.8 % w/v) containing ethidium bromide (0.1 µ g/ml) and visualized by UV-exposure.
The images of the amplified cDNA bands were captured by Olympus μ -7000 digital camera.
Sequence aliment analysis of RBMs:
The sequences from Homo sapiens RBM10v1 (NP_005667), RBM10v2 (NP_690595) and RBM5 (NP_005769) were aligned using the Cluster W multiple aliment algorithm (Vector NTI suite 7.0 AlignX). The carboxyl terminal 231 residues of RBM10v2, RBM10v1 and RBM5 were aligned and the highly conserved motifs were indicated.
Results
High expression levels of RBM10v1 and RBM5 in COS-7 and HeLa cells: COS-7, HeLa, A549 and HK-2 cells differentially expressed RBM10v1, RBM10v2 and RBM5 proteins as shown in Fig. 1A . HeLa and COS-7 cells expressed a higher level of RBM10v1and RBM5. A549 cells expressed a low level of RBM5 as previously described (33, 34) . HK-2 cells expressed the lowest levels of the RBMs. A549, HeLa and COS-7cells expressed RBM10v1 protein at twofold, fourfold and twelve-fold more than HK2 cells as shown in Fig.1A -a. A549, HeLa and COS-7 cells expressed a twofold, fourfold and six fold more amount of RBM10v1 over the RBM10v2 levels, respectively. A549, HeLa and COS-7 cells expressed a twofold, fourfold and sevenfold more RBM5, respectively, compared to HK-2 cells as shown in Fig. 1A-b . The nuclear extract of HeLa cells contained a twofold more RBM10v1 and a fourfold more RBM5 proteins compared to those of young TIG3S fetal fibroblasts ( Fig. 1A-d ). The overexpressions of the RBMs of the transformed cells are a novel finding but the molecular mechanism has not been clarified.
A positive correlation of the expression of both RBM10v1 and RBM5 was reported in human tumor tissues previously (35) . In addition, strongly upregulated RBM mRNAs including RBM10 were found in nine cancers (36). Therefore, the higher protein levels of RBM10v1 and RBM5 seemed to be a characteristic of the highly proliferative tumor cells.
Effects of antitumor agents on the stability of RBM proteins:
Unstressed HeLa cells expressed the tiny RBM10 nuclear granules (25). Under normal culture condition, the nuclear speckles were not prominent in the actively growing A549 cells ( Fig.2A ). Hence, COS-7 cells were transfected with the expression vector of RBM10v1-GFP and N-terminally truncated
RBM10v2
[ #482-852]-RFP, and thereby the prominent nuclear speckles could be observed as shown in Fig. 2B . This result suggests that RBM10v2 [#482-852] preserves the structural elements for the nuclear speckles localization as discussed later.
The effects of DOX and AcD on the expression of RBM10 and RBM5 were characterized. At first, A549 cells were exposed to DOX at a low therapeutic dose for 20 hours, and then the RBM10 immunofluorescent signals were examined. The treatment with 0.5 µM or 1 µM DOX decreased the RBM10 immunofluorescent signals as indicated by blue arrows in the middle and right panels of Fig.2C . In contrast, the non-treated cells kept the higher RBM10 signals as shown in the left panels of Fig. 2C . Interestingly, the DOX exposure did not promote the RBM10 nuclear speckles in A549 cells.
The drug sensitivity of the RBMs in COS-7 cells was quantitatively investigated as follows. The RBM proteins were examined after exposure to 1 µM DOX or 1 µM AcD as shown in As noted above, DOX and AcD differentially affected the stability of RBM10 and RBM5. It is known that DOX and AcD activate caspase-2 and caspase-3 in normal or tumor cells. Thereby the RBMs become sensitive to proteolysis in circumstances of cancer chemotherapy. Accordingly, the putative caspase cleavage sites of the RBMs were searched by Expasy PeptideCutter tool that predicts protease sites (40). The results showed no caspase cleavage site of RBM10 and one caspase-1 cleavage site of RBM5 at #90D (YRHDISDE), which suggests its higher sensitivity to AcD.
Proteasome-dependent nuclear protein degradation occurs in the distinct nuclear domains that overlap with ubiquitin, splicing speckles or PML bodies (41). Active PA28γ-proteasome complexes localize in the nuclear speckles and control the nuclear traffiking of splicing factors though selective proteolysis(42). DOX-mediated activation of ubiquitin proteasome system (UPS) was surveyed in cardiomyocytes or K562 erythroleukemic cells (18, 43, 44) and in vivo or in vitro (45). DOX induced the DNA damage of H1299 non-small cell lung carcinoma cells and triggered the increase of proteasome activity, of which caspase-like and chymotrypsin-like activities were 30% higher than non-treated cells (46).
Small ubiquitin-like modifier (SUMO) is identified as a targeting signal for ubiquitylation and ubiquitin-dependent degradation as reviewed by Miteva et al., (47) . Interestingly, DOX specifically and significantly accelerated the proteasome-mediated proteolysis of transcription coactivator p300 and transcription factor NFAT5 in cardiomyocytes (48, 49) .
Hence, I applied the SUMO prediction algorithm (50,51) to predict the sumoylation sites of RBM10v2, RBM5, NFAT5 and p300. The algorithm revealed that RBM10v2 (or RBM10v1) has 3 sumoylation sites including lysine residues at #54K, #163K and #458K and three SUMO-interaction motifs (SIMs) at #254-258, #681-685 and #806-810 as described in Table1.
In contrast, RBM5 has one sumoylation site at #181Kand two SIMs at #262-266 and #647-651. Interestingly, p300 or NFAT5 has six or seven sumoylation sites, respectively and two SIMs. Taken together, the bioinformatics analysis supports that proteasome mediates the degradation of RBM10, NFAT5 and p300.
Actinomycin D promotes the targeting of RBM10v2 and RBM5 to the nuclear speckles: COS-7 cells were transfected with the pRBM10v2-RFP construct, cultured for 48 hours and followed in the medium containing DOX. Red fluorescence of the RBM10v2-RFP and green fluorescence imaging of the endogenous RBM10 were examined. RBM10v2-RFP diffusely localized in the nucleoplasm of many cells ( cells were transfected with the pRBM5-GFP construct, and RBM5-GFP localized diffusely in the nuclei (Fig.5C ). Upon a 3 hour exposure to AcD, the targeting of RBM5-GFP to the nuclear speckles was promoted ( Fig.5D ).
Structural elements of RBM10 targeting to the nuclear speckles were explored as described below. -852] . Hence, it is likely that RBM10v2[#681-759, #681-852] has a N-terminally exposed SIM LACLL and a nucleolar targeting element, whereas the N-terminal region RBM10v2[#648-680] seems to mask the nucleolar targeting element.
The motif of nucleolar localization signal contains (R/K) (R/K) X (RK) or (R/K) X(R/K) (R/K) as reported previously (52).
Histone H2B has a nucleolar retention signal sequence, KKRKRSRK (53). Moreover sumoylation of nucleoplasmin/B23 is necessary for its nucleolar residency and function (54 (56) .
Effects of antitumor agents to RBM10 and RBM5: DOX enhanced the proteasome or UPS-mediated degradation of cardiac troponins, cardiac transcription factors and survival factors (18, 49, 57) . DOX specifically enhanced the degradation of nuclear protein p300 and nuclear factor-activated T cell 5 in the cultured cardiomyocytes (48, 49) . Similarly, the present study revealed that RBM10 of the DOX-exposed COS-7 cells was highly sensitive to proteolysis.
In HeLa or COS-7 cells, a 3 hour exposure to AcD induces the RBM6 nuclear speckles (24). Upon a 24 hour exposure to 0.8 µM AcD, HeLa cells decreased the endogenous snRNP and SC35 proteins (58). In the present investigation, COS-7 cells were transfected with the expression vector of RBM10-RFP and followed with a short time-exposure to AcD, resulting in the prominent nuclear speckles of the endogenous RBM5 and RBM10v2-RFP.
Mitoxantrone (MTX) is a structurally DOX-related topoisomerase II inhibitor. When A549 cells were treated with 2.5 µM MTX for 24 hours, the RBM10v1 and RBM10v2 mRNA mostly disappeared, but RBM5 mRNA mostly remained unchanged (data not shown). MTX also differentially triggered the decay of RBM10 mRNA.
Nuclear speckles of RBM10 and PML nuclear bodies:
The nuclear speckles of RBM10 and RBM5 were more prominent in the AcD-exposed cells. Next, the structural elements of the RBM10 nuclear speckles were investigated. COS-7 cells were transfected with the N-terminally truncated RBM10v2-RFP construct that lacks the N-terminal 481 or 641 residues. The and Zing finger C 2 H 2 are the nuclear speckles targeting sequences in ARL cells (rat liver epithelial cells) (59). The differential localization of the truncated RBM10 might occur in the above two cell systems. Of course, RBM10v2 shares the low sequence identities, 11.4% and 9.8% with PML-Ⅳ and PML-Ⅵ, respectively. The SUMO prediction algorithm predicted one sumoylation site (#386K) of p53 and a SIM (#143-147: VQLWV) at the p53 core domain, a specific fourth sumoylation site (#616K) of PML-Ⅳ and a SIM (#550-560: VVVIS) as described in Table 1 .
RFP-fusion of RBM10v2
Interestingly, PML-Ⅵ lacks the above two motifs. Accordingly, I explored a certain interaction of RBM10 with PML-Ⅳ, and p53 as described below. In COS-7 cells, the coexpressed RBM10v2-RFP and PML-Ⅵ-GFP did not colocalize on the nuclear speckles or nuclear bodies (supplement Fig. S3-A) . This suggests no specific interaction between RBM10v2 and PML-Ⅵ. However, RBM10v1-RFP and RBM5-GFP colocalized on the nuclear speckles (supplement Fig. S3-B) , as previously described. Similarly, the nuclear speckles of RBM10v2-RFP and RBM10v2[#642-852]-RFP colocalized on the nuclear bodies of PML-Ⅳ-GFP (supplement Fig. S3-C) . This demonstrated a certain interaction between the two proteins.
Furthermore, p53-GFP colocalized with the nuclear speckles of RBM10v2-RFP in human fibroblasts (data not shown). Taken together, these results suggest that structurally unrelated proteins, RBM10, PML-Ⅳor p53 undergo sumoylation and interact through the attached SUMO and SIMs. Sumoylation and SUMO-interaction sites in RBM10, RBM5, NFAT5 and p300. Sumoylation site SUMO-interaction motifs (SIM) RBM10v2 (852AA) Ac#:NP_690595
#160 (EAHQWFLKHEARPLA) lack Ac#: AAA60125 #226 (DSSHSELKCDISAEI) #490 (QCPRKVIKMESEEGK) Prediction of sumoylation site and SIM were performed at medium threshold setting of the SUMO prediction algorithm (GPS-SUMO1.0).
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show the significant reduction of RBM10 or RBM5 protein. White asterisks show the significant resistance of the RBM proteins. (B) RBM10 mRNAs of COS-7 cells exposed to DOX or AcD for 6 and 16 hours. Non-treated cells (indicated as C) or H9c2 cells were cultured without drugs. (C) RBM10 and Fas mRNAs of HeLa cells exposed to DOX or AcD for 16 hours (right panel). The total RNA was reverse transcribed and subjected to RTPCR. The endogenous mRNA levels of RBM10v1 (901bp), RBM10v2 (670bp), RBM5 (389bp), Fas 5-7 (150bp) or GAPDH (500bp) were determined by Image-Pro Plus software. The middle band between the both RBM10 variants, RBM10v3 was rarely observed. The numbers above the cDNA bands show the relative mRNA levels. Significant reduction or increase was indicated by white asterisk. 
Supplemental materials captions:
Supplement Fig. S1 . Differential sensitivities of RBM10 and RBM5 to Doxorubicin or AcD. COS-7 (A) or HeLa cells (B) were exposed to DOX or AcD for 6 and 16 hours as described previously. The protein levels of RBM10, RBM5 and β -actin were shown as graph bar plots. Black or red asterisks denote the resistance or sensitivity of the proteins, respectively.
Differential drug sensitivities of RBM10 and RBM5 protein were demonstrated. 
